From Assisted Hatching to Embryo Glue, Most IVF ‘Add-ons’ Rest on Shaky Science, Studies Find
By Sharon Begley,
STAT
| 11. 05. 2019
By the time Sarah Chamberlin’s fertility doctor declared her genes “incompatible” with her husband’s and said the clash might be preventing her from having children, she’d had five rounds of artificial insemination and two cycles of in vitro fertilization — and precisely zero pregnancies. So when the physician suggested she try a drug that is ordinarily prescribed to cancer patients, to get her immune system to stop attacking her embryos, she didn’t hesitate.
“I was 41 by then,” said Chamberlain, 47, who lives on New York’s Long Island and at the time was a consultant at her husband’s restaurant. “When they say they have one more thing you can try, it gives you hope.”
She had already spent tens of thousands of dollars in an effort to conceive — her insurance didn’t cover assisted reproduction — and had grown inured to the fertility-related shots that turned her into a human pin cushion. With all she had been through, it seemed foolish to hesitate over six additional daily injections and another $3,000 for the drug, called Neupogen; the idea that she...
Related Articles
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...